IDRA-21

Quality 0.50 · 1 view · Updated 2 months ago

Chemical compound

title: "IDRA-21" type: doc version: 1 created: 2026-02-28 author: "Wikipedia contributors" status: active scope: public tags: ["ampa-receptor-positive-allosteric-modulators", "benzothiadiazines", "chloroarenes", "experimental-drugs", "nootropics"] description: "Chemical compound" topic_path: "general/ampa-receptor-positive-allosteric-modulators" source: "https://en.wikipedia.org/wiki/IDRA-21" license: "CC BY-SA 4.0" wikipedia_page_id: 0 wikipedia_revision_id: 0

::summary Chemical compound ::

| Verifiedfields = changed | verifiedrevid = 424673085 | IUPAC_name = 7-chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide | image = IDRA-21.svg | image_class = skin-invert-image | width = 200px

| tradename = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = Investigational New Drug | legal_status = | routes_of_administration =

| bioavailability = | protein_bound = | metabolism = | excretion =

| CAS_number_Ref = | CAS_number = 22503-72-6 | UNII_Ref = | UNII = 689UW7PT68 | IUPHAR_ligand = 4219 | ATC_prefix = | ATC_suffix = | PubChem = 3688 | DrugBank_Ref = | DrugBank = | ChemSpiderID_Ref = | ChemSpiderID = 3560 | ChEMBL_Ref = | ChEMBL = 77862

| C=8 | H=9 | Cl=1 | N=2 | O=2 | S=1 | smiles = CC1NC2=C(C=C(C=C2)Cl)S(=O)(=O)N1 | synonyms = | StdInChI_Ref = | StdInChI = 1S/C8H9ClN2O2S/c1-5-10-7-3-2-6(9)4-8(7)14(12,13)11-5/h2-5,10-11H,1H3 | StdInChIKey_Ref = | StdInChIKey = VZRNTCHTJRLTMU-UHFFFAOYSA-N

IDRA-21 is a positive allosteric modulator of the AMPA receptor and a benzothiadiazine derivative. It is a chiral molecule, with (+)-IDRA-21 being the active form.

IDRA-21 shows nootropic effects in animal studies, significantly improving learning and memory. It is around 10–30 times more potent than aniracetam in reversing cognitive deficits induced by alprazolam or scopolamine, and produces sustained effects lasting for up to 48 hours after a single dose. The mechanism for this action is thought to be through promoting the induction of long-term potentiation between synapses in the brain.

IDRA-21 may not produce neurotoxicity under normal conditions, although it may worsen neuronal damage following global ischemia after stroke or seizures.

In comparison to the ampakines or benzoylpiperidine-derived AMPA receptor potentiators, IDRA-21 was more potent than CX-516, but less potent than CX-546. Newer benzothiadiazide derivatives with greatly increased potency compared to IDRA-21 have been developed, but these have not been researched to the same extent, with the benzoylpiperidine and benzoylpyrrolidine CX-series of drugs being favoured for clinical development, most likely due to more favourable toxicity profiles at high doses.

References

References

  1. (August 1995). "Enantiomeric resolution with a new chiral stationary phase of 7-chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine S,S-dioxide, a cognition-enhancing benzothiadiazine derivative". Journal of Pharmaceutical Sciences.
  2. (August 1995). "7-Chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine S,S-dioxide (IDRA 21), a congener of aniracetam, potently abates pharmacologically induced cognitive impairments in patas monkeys". Proceedings of the National Academy of Sciences of the United States of America.
  3. (January 1995). "7-Chloro-3-methyl-3-4-dihydro-2H-1,2,4 benzothiadiazine S,S-dioxide (IDRA 21): a benzothiadiazine derivative that enhances cognition by attenuating DL-alpha-amino-2,3-dihydro-5-methyl-3-oxo-4-isoxazolepropanoic acid (AMPA) receptor desensitization". The Journal of Pharmacology and Experimental Therapeutics.
  4. (January 2004). "The effects of IDRA 21, a positive modulator of the AMPA receptor, on delayed matching performance by young and aged rhesus monkeys". Neuropharmacology.
  5. (September 1996). "Effect of the AMPA receptor modulator IDRA 21 on LTP in hippocampal slices". NeuroReport.
  6. (June 1997). "7-Chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine S,S-dioxide: a partial modulator of AMPA receptor desensitization devoid of neurotoxicity". Proceedings of the National Academy of Sciences of the United States of America.
  7. (May 1998). "The diazoxide derivative IDRA 21 enhances ischemic hippocampal neuron injury". Annals of Neurology.
  8. (November 2001). "Mechanism and impact of allosteric AMPA receptor modulation by the ampakine CX546". Neuropharmacology.
  9. (May 2002). "5'-alkyl-benzothiadiazides: a new subgroup of AMPA receptor modulators with improved affinity". Bioorganic & Medicinal Chemistry.
  10. (September 2002). "Effects of 5'-alkyl-benzothiadiazides on (R,S)-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor biophysics and synaptic responses". Molecular Pharmacology.
  11. (April 2005). "Therapeutic potential of positive AMPA modulators and their relationship to AMPA receptor subunits. A review of preclinical data". Psychopharmacology.

::callout[type=info title="Wikipedia Source"] This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page. ::

ampa-receptor-positive-allosteric-modulatorsbenzothiadiazineschloroarenesexperimental-drugsnootropics